← All trials
NCT05224401
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 10, 2023
- Primary completion
- Sep 1, 2027
- Completion date
- Sep 1, 2027
- First posted
- Feb 4, 2022
- Last posted
- Nov 23, 2022
- Enrollment
- 330
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Lund UniversityLead sponsor
- Lund UniversityOverall official - principal investigator
- Lund UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.